RxDoctor Payments DataLook up a doctor →

Samuel Sanchez, MD

Dermatology · Caguas, PRNPI 1154543221

Payments from drug & device makers

$1,613,132in general payments, 2019–2025

Across 458 payments — averaging $3522.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$936K
  • Eli Lilly Export S.A. Puerto Rico Branch$533K
  • E.r. Squibb & Sons, L.L.C.$80K
  • Amgen$27K
  • Eli Lilly$15K
  • Incyte Corporation$13K
  • plus $9K from 8 others
$251,770in research payments, 2019–2025

Across 44 payments — averaging $5722.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$141K
  • E.r. Squibb & Sons, L.L.C.$56K
  • Sanofi US Services Inc.$18K
  • Eli Lilly$17K
  • Amgen$10K
  • Eli Lilly Export S.A. Puerto Rico Branch$10K

What the payments were for

  • Consulting fees$14,49958%
  • Speaking & faculty fees$5,92524%
  • Travel & lodging$380%
  • Food & beverage$4,03016%
  • Education$4712%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,613,132 in reported general payments places this provider in the 95th percentile of 108 dermatology providers in Puerto Rico.

See all dermatology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$6,201
Medicare patients
30
Services billed
76

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TremfyaGuselkumab26$356,025
Taltz AutoinjectorIxekizumab25$167,530
RinvoqUpadacitinib24$156,066
Humira(Cf) PenAdalimumab13$90,994
Dupixent PenDupilumab22$84,043
Ketoconazole536$12,333
Betamethasone Valerate295$11,583
Ciclopirox218$9,951
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc120$6,986
CiclopiroxCiclopirox Olamine179$6,787
Metronidazole80$4,312
Clobetasol Propionate64$3,958
Fluorouracil44$3,454
Desonide99$3,328
Triamcinolone Acetonide136$1,704

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$1,705$356,02526 claims
AbbVieRinvoq$936,230$156,06624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 108 dermatology providers in Puerto Rico.

Other dermatology in Caguas

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →